[目的]探讨外周血髓源抑制细胞水平(MDSC)及NLR和PLR比值在结肠癌中的意义.[方法]提取166例结肠癌患者和100名健康体检人员外周血,进行MDSC检测和NLR和PLR检测.[结果]结肠癌组术前MDSC比例明显高于正常组(P＜0.05),术后6个月低于术前;结肠癌组术前外周血中NLR水平明显高于正常组(P＜0.05),术后6个月显著低于术前(P＜0.05);结肠癌组术前外周血中PLR水平明显高于正常组(P＜0.05),术后6个月显著低于术前(P＜0.05).MDSC、NLR和PLR水平与结肠癌患者肿瘤大小、TNM分期、淋巴转移有关(P均＜0.05).TNM分期、淋巴转移是影响结肠癌生存的主要因素(P＜0.05).[结论]结肠癌外周血MDSC及NLR和PLR水平明显升高,对预后判断有一定价值.

目的 探讨血清miR-195在非小细胞肺癌(NSCLC)患者中的表达及其临床意义.方法 采用实时荧光定量PCR(qRT-PCR)检测100例非小细胞肺癌患者和90例正常健康体检者血清miR-195的表达量,结合临床资料分析其表达在临床中的作用和意义.结果 与正常人群相比,NSCLC患者血清miR-195相对表达量降低(7.26±1.61 vs.4.52±1.17,P<0.01);Ⅲ～Ⅳ期NSCLC患者血清miR-195相对表达量低于Ⅰ～Ⅱ期患者,有淋巴结转移的NSCLC患者血清miR-195相对表达量低于无淋巴结转移者,有远处转移的NSCLC患者血清miR-195相对表达量低于无淋巴结转移者,差异均有统计学意义(P<0.05),而血清miR-195相对表达量在鳞癌和腺癌患者中无统计学差异,在高分化、中分化、低分化患者中也无统计学差异;Logistic回归分析结果显示,miR-195相对表达量(OR=0.526,95％CI:0.415～0.697,P=0.007)与NSCLC密切相关;血清miR-195相对表达量诊断NSCLC的AUC为0.875(95％CI:0.826～0.923,P=0.004);血清中高表达miR-195的NSCLC患者中位生存时间明显长于血清中低表达miR-195者(P<0.05),多因素分析表明血清miR-195相对表达量是NSCLC预后的独立影响因素(HR=0.615,95％CI:0.324～0.783;P=0.011).结论 NSCLC患者血清miR-195表达量降低,并且与NSCLC的分期、淋巴转移、远处转移和预后关系密切,血清miR-195有望成为NSCLC潜在的早期诊断、预后评价的分子标志物.

Objective To investigate the cancer pain status and cancer pain control satisfactory in Longquanyi District of Chengdu city,in order to provide the basis for the improvement of local cancer pain management. Methods The self-designed pain questionnaire survey was conducted on 450 cancer patients who were diagnosed and treated in oncology department of three hospi-tals from January 2015 to December 2015 in the area. Results The incidence rate of cancer pain was 49. 8% in 450 cancer pa-tients,and the satisfaction rate of cancer pain control was 70. 1%. For the main factors affecting cancer pain control satisfactory,the survey showed that for physician they were poor patient compliance,not smooth drug supply,and insufficient dosage; for patients they were fear of adverse drug reaction,refusing to use or refusing to increase the amount because of fear of addiction,and poor an-algesic effect of oral drugs. Conclusion Cancer pain management in Longquanyi District of Chengdu city is insufficient, which needs further training and education about the treatment knowledge of cancer pain, and needs to promote the implementation of standardized treatment of cancer pain in primary hospitals.

目的：评价复方难治性非霍奇金淋巴瘤采用氟达拉滨联合表柔比星治疗的临床效果。方法：40例复方难治性非霍奇金淋巴瘤为对照组采用氟达拉滨治疗，35例复方难治性非霍奇金淋巴瘤为研究组采用氟达拉滨联合表柔比星治疗，比较分析不同治疗方法治疗效果以及无病生存率。结果：研究组患者的第4个疗程缓解率优于第1个疗程缓解率，且高于对照组第4个疗程的缓解率，研究组第1年、2年生存率显著优于对照组，P<0.05有统计学意义。结论：复方难治性非霍奇金淋巴瘤患者接受氟达拉滨联合表柔比星治疗，疗效显著。